Confident Investing Starts With TipRanks Premium

Get 55% Off
TipRanks
Go Ultimate55% OFF

GE Healthcare Technologies Inc (1GEHC) Drug Pipeline

Drug pipeline
Drug NameConditionStageStatusStudy NameTrial Start DateArticle
Gadobutrol, Mri Scan, Mangaciclanol, Also Known As Geh200486 Injection, 0.5 Mmol/MlKnown Or Highly Suspected Central Nervous System (Cns) Lesion, Known Or Highly Suspected Body (Excluding Cns) Lesionphase2AndPhase3RecruitingA Phase 2/3 Study on the Efficacy and Safety of Mangaciclanol for Contrast-Enhanced MRI of CNS or Body in Adult PatientsFeb 12, 2026
Contrast-Enhanced UltrasoundFocal Liver LesionsPhase IVRecruitingPhase 4 Paediatric Study to Evaluate Sonazoid Safety and Efficacy for Contrast-Enhanced Ultrasound Liver ImagingOct 01, 2024
Static - Pet/Ct Scan, Dynamic And Static - Pet/Ct Scan, Geh200520 Injection / Geh200521 Injection - Part A, Geh200520 Injection / Geh200521 Injection - Part BOncology, Malignant Solid TumorPhase ITerminatedA Study to Evaluate GEH200520/GEH200521 (18F) Safety and Tolerability When Used for PET Scans in Patients With Solid Tumour MalignanciesOct 11, 2022―

FAQ

What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases: a. Preclinical testing b. Phase 1 – Safety and dosage c. Phase 2 – Effectiveness and side effects d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Ge Healthcare Technologies Inc. (IT:1GEHC) have in its pipeline
GE Healthcare Technologies Inc IT:1GEHC is currently developing the following drugs: Gadobutrol, Mri Scan, Mangaciclanol, Also Known As Geh200486 Injection, 0.5 Mmol/Ml, Contrast-Enhanced Ultrasound, Static - Pet/Ct Scan, Dynamic And Static - Pet/Ct Scan, Geh200520 Injection / Geh200521 Injection - Part A, Geh200520 Injection / Geh200521 Injection - Part B. These drug candidates are in various stages of clinical development as the company works toward FDA approval.